Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 1192 for:    adenosine

Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02284048
Recruitment Status : Unknown
Verified November 2014 by Daoquan Peng, Second Xiangya Hospital of Central South University.
Recruitment status was:  Not yet recruiting
First Posted : November 5, 2014
Last Update Posted : November 6, 2014
Sponsor:
Information provided by (Responsible Party):
Daoquan Peng, Second Xiangya Hospital of Central South University

Brief Summary:
This study is undertaken to determine if ticagrelor augments adenosine-induced coronary flow reserve (CFR), ameliorates clinical symptomatology and exercise tolerance in patients with MVA

Condition or disease Intervention/treatment Phase
Microvascular Angina Drug: ticagrelor Phase 4

Detailed Description:
Considering the reduced CFR and increased platelet aggregability in patients with MVA, together with the augmented effect on adenosine-mediated coronary blood flow and potent antiplatelet effect of ticagrelor, we speculate that ticagrelor can promisingly ameliorate the coronary microvascular function in patients with MVA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
Study Start Date : November 2014
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : November 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina

Arm Intervention/treatment
Placebo Comparator: control
nitrate,beta blocker
Drug: ticagrelor
compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
Other Name: Brilinta

Active Comparator: ticagrelor
ticagrelor 90mg qd
Drug: ticagrelor
compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
Other Name: Brilinta




Primary Outcome Measures :
  1. adenosine-induced coronary flow reserve (CFR) [ Time Frame: 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

For inclusion in the study subjects should fulfill the following criteria:

  1. Provision of informed consent prior to any study specific procedures
  2. Female or male aged 18-80 years
  3. A diagnosis of stable primary MVA based on the presence of

    • a history of typical effort angina,
    • exercise-induced ST-segment depression>1 mm,
    • normal or near-normal (coronary artery stenosis<50%) coronary angiography,
    • absence vasospastic angina
    • a coronary flow reserve (CFR) <2.5 in the left anterior descending coronary artery as assessed by coronary blood flow (CBF) response to adenosine at transthoracic Doppler echocardiography
    • suboptimal control of symptoms on conventional anti-ischemic therapy, as indicated by the occurrence of >1 episode per week of angina

Exclusion Criteria:

ubjects should not enter the study if any of the following exclusion criteria are fulfilled:

  1. concomitance with any of the cardiac condition below

    • significant (>50%)coronary plaque disease
    • coronary artery spasm at angiography or other evidence of vasospastic angina
    • valvular or other structural heart disease
    • uncontrolled hypertension
    • abnormal echocardiographic examination including left ventricular hypertrophy
  2. no previous consumption of the ticagrelor
  3. no apparent contraindications to ticagrelor administration.

    • History of Intracranial Hemorrhage
    • Active Bleeding
    • Severe Hepatic Impairment: AST and ALT are greater than 3 times of the upper limit. Bilirubin is greater than the upper limit.
    • hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product
    • severe COPD or asthma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02284048


Contacts
Layout table for location contacts
Contact: Daoquan Peng, MD, PhD 86-731-85295806 pengdq@hotmail.com

Sponsors and Collaborators
Second Xiangya Hospital of Central South University
Investigators
Layout table for investigator information
Study Chair: Daoquan Peng, MD, PhD Second Xiangya Hospital of Central South University

Layout table for additonal information
Responsible Party: Daoquan Peng, Professor, Second Xiangya Hospital of Central South University
ClinicalTrials.gov Identifier: NCT02284048     History of Changes
Other Study ID Numbers: ISSBRIL0217
First Posted: November 5, 2014    Key Record Dates
Last Update Posted: November 6, 2014
Last Verified: November 2014
Keywords provided by Daoquan Peng, Second Xiangya Hospital of Central South University:
Ticagrelor
Coronary Flow Reserve
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenosine
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Ticagrelor
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists